title: [Screening for tuberculosis infection prior to medical therapy].
abstract: Tumour necrosis factor antagonists (anti-TNFα) have become an invaluable treatment against chronic inflammatory diseases. Individuals treated with anti-TNFα have more than a fourfold increased risk of tuberculosis (TB) reactivation depending on the clinical setting and the TNF-antagonist used. All candidates for anti-TNFα treatment in Denmark should be evaluated for possible latent TB using history of exposure, chest X-ray and an interferon-γ release assay. Preventive chemotherapy is recommended for all individuals with latent TB infection before initiation of anti-TNFα as it is expected to reduce the risk of progression to active TB.
authors.affiliation: Infektionsmedicinsk Afdeling O 107, Herlev Hospital, 2730 Herlev, Denmark. pravn@dadlnet.dk
authors.forename: Pernille
authors.initials: P
authors.lastname: Ravn
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D006801:Humans; D007159:Immunologic Tests; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007371:Interferon-gamma / Q000378:metabolism; D055985:Latent Tuberculosis / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D012307:Risk Factors; D014374:Tuberculin Test; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma